Author

Jeffrey J. Liu

Amgen (United States)ORCID 0000-0003-2147-6449Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Arghya Sadhukhan· 1 shared Cory M. NadeliD· 1 shared Kate S. Ashton· 1 shared Kyle ManganoiD· 1 shared Patrick Ryan PottsiD· 1 shared Rajiv Kapoor· 1 shared Robert G. GuenetteiD· 1 shared Seung Wook YangiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Arghya Sadhukhan

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation

Kyle Mangano, Robert G. Guenette, Spencer Hill, Shiqian Li, Jeffrey J. Liu, Cory M. Nadel, Suresh Archunan, Arghya Sadhukhan, Rajiv Kapoor, Seung Wook Yang, Kate S. Ashton, Patrick Ryan Potts

The paper demonstrates VIPER-TACs, which use viral E3 ligases to selectively degrade disease-specific proteins, reducing toxicity and expanding therapeutic options for targeted protein degradation.

Cell chemical biology · Mar 1, 2025Peer-reviewedCancer Biology